SwanBio Therapeutics Appoints Zelenkofske Chief Medical Officer

Gene therapy developer SwanBio Therapeutics has appointed Steven Zelenkofske to serve as its chief medical officer, the same role he held most recently at Achillion Pharmaceuticals, which was acquired by Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]) last year. His experience also includes positions at uniQure (NASDAQ: [[ticker:QURE]]), Regado Biosciences, AstraZeneca (NYSE: [[ticker:AZN]]), Sanofi-Aventis, Boston Scientific (NYSE: [[ticker:BSX]]), and Novartis (NYSE: [[ticker:NVS]]). Bala Cynwyd, PA-based SwanBio is developing gene therapies to address neurological disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan